Home Blog

Grow for Vets USA Announces Free Medical Cannabis for Veterans in Las Vegas

Grow for Vets USA Announces Free Cannabis for Veterans in Las Vegas
 

LAS VEGAS, July 25, 2017 (STL.NEWS) — Grow For Vets USA,™ a national tax-exempt organization that has given away more than $1.4 million of free medical cannabis products to Veterans of the United States Armed Forces, today announced plans to host one of their signatures free medical cannabis giveaway events for Veterans, in Las Vegas, Nevada.

According to Grow for Vets USA™ founder and U.S. Army Veteran, Roger Martin, Veterans attending this event will receive a free cannabis ‘Go Bag’ containing a variety of donated cannabis and hemp oil-based products.

More than 1,200 Veterans attended this free medical cannabis giveaway event in Colorado Springs, CO.
More than 1,200 Veterans attended this free medical cannabis giveaway event in Colorado Springs, CO.
All cannabis products originating from private donors have been tested and certified safe by DB Labs of Las Vegas. Martin noted that “DB Labs is our Official Nevada Testing Lab. They are Nevada’s best testing lab and they ensure that the cannabis products we give Veterans are safe. Other sponsors playing a key role in this event include Las Vegas’ own dr.dabber and Elevate Nevada. National brands including O.penVAPE, Urban Ag, Boveda, Incredibles, Bee-Nails, along with Official Media Partner mg Magazine, have been instrumental in putting on this event.”

When asked why to Grow for Vets provides Veterans with free medical cannabis, Martin said, “More than one million Veterans are presently at risk of dying from an opiate overdose.”

Martin further noted that in 2016, “More American heroes died from prescription drug overdose and suicide than all military personnel killed in combat in every year combined, since the end of the Vietnam War more than 40 years ago.”

EVENT DETAILS

Event Date and Time: July 29, 2017 • 11 a.m. – 1:00 p.m.

Event Location: The Fortune Hotel & Suites • 325 East Flamingo Road, Las Vegas

RSVP Required: http://growforvets.org/events/#!event-list

RSVP Deadline: Thursday, July 27, 2017, at 5:00 p.m. PDT

Cost: FREE to all Veterans and up to 2 guests

Please note that this event is open to Grow for Vets members only. Veterans wishing to join Grow for Vets can do so online at www.GrowForVets.org. Membership is free.

About Grow for Vets USA
Grow for Vets USA has given away more than $1.4 million dollars in medical cannabis products to American heroes. The mission of Grow for Vets USA is to help save the staggering number of Veterans who die each day from suicide and prescription drug overdose. We provide Veterans with the knowledge and resources necessary to obtain and/or grow their own cannabis medicine. We are working to raise awareness by enlisting the public’s aid and support in ensuring that all wounded, injured, and ill Veterans receive the respect and dignity of life that they deserve. Our purpose is to provide Veterans with unique products, programs, and services designed to assist them in living with injuries sustained while protecting our freedom. Grow for Vets USA is a national, nonpartisan, tax-exempt organization headquartered in Las Vegas, Nevada. To get involved or to learn more, please visit www.GrowForVets.org.

Media Contact:
Lori Martin
Phone: 720.641.8496
Email: [email protected]

Grow for Vets USA’s medical cannabis related activities are conducted only within jurisdictions allowing such activities. All cannabis and cannabis related products distributed by Grow for Vets USA are grown and manufactured within the state in which they are distributed. Grow for Vets USA is a 501(c)(19) tax-exempt, nonprofit organization.

LDI Integrated Pharmacy Services Appoints Bruce Lyons to Board of Directors

LDI Integrated Pharmacy Services Appoints Bruce Lyons to Board of Directors
 

ST. LOUIS, July 26, 2017 (STL.NEWS) — LDI Integrated Pharmacy Services is pleased to announce they have expanded their Board of Directors with the appointment of Bruce Lyons. Mr. Lyons brings expertise that aligns perfectly with the LDI commitment to offer healthcare payers a successful path to reducing their pharmacy costs, using an innovative approach that links technology with high-touch member care.

CEO Len Dino said: “It’s an honor to welcome Bruce, a highly- respected executive known for his leadership, integrity and deep strategic expertise within the pharmacy benefits industry, to the LDI Board of Directors. Bruce joins LDI at a pivotal time as we build on our 50-year legacy of delivering high-touch pharmacy benefit services to plan sponsors and lay the foundation for our future.”

“There are deep challenges confronting healthcare payers and pharmacy benefits are a critical component of managing healthcare costs,” said Bruce. “LDI Integrated Pharmacy Services has a rich history of partnering with clients to understand their priorities and work proactively to solve their cost management challenges. I am looking forward to working with the LDI executive team.”

LDI is committed to recruiting the very best, most talented leaders across the company as demonstrated by this latest addition to their Board. Mr. Lyons brings decades of executive experience leading high-performance sales and account service divisions within the pharmacy benefit management industry. In his most recent position as Senior Vice President, Employer Sales and Account Services at CVS Health, Mr. Lyons had full P&L responsibility for all new business sales, account retention and client support services. This included sales and service to the Employer, Coalition, Government, TPA and Medicare Part D markets.

About LDI Integrated Pharmacy Services
Founded in 1967 by pharmacists, the company provides pharmacy benefits management for health insurers, third party administrators and a variety of self-insured organizations. Today we are a trusted partner to hundreds of payers looking for proven ways to manage their pharmacy drug benefit. Our clients take advantage of our specialty and mail order pharmacies, retail network and a comprehensive set of clinical programs that provide high-touch support to plan members to help them achieve their treatment goals. For more information, please visit www.ldirx.com.

SOURCE LDI Integrated Pharmacy Services

TenantCloud Quarterly Finds U.S. Rental Occupancy Highest in Nearly 25 Years

TenantCloud Quarterly Finds U.S. Rental Occupancy Highest in Nearly 25 Years
 

AUSTIN, TX JULY 26, 2017 (STL.NEWS)  Today, TenantCloud, the premier cloud-based property management solution, launched The TenantCloud Quarterly to provide ongoing insight and analysis of real estate trends. Based on company data and a survey of landlords within TenantCloud’s network, the latest report shows that U.S. rental occupancy rates are at the highest rate since 1993 and the country saw the largest percentage rent increase from January to March. As a result, many people are jumping into the rental market as first-time landlords, two-thirds of TenantCloud landlords polled classify themselves as “part-time” landlords, and more than one-third have been a landlord for less than five years.
“With the ups and downs of the housing market over the last decade, we’ve seen rental occupancy spike at the highest rate since 1993,” said Joe Edgar, CEO of TenantCloud. “As a result, many people are jumping into the rental market as first-time landlords, which is why we’re committed to providing a one-stop shop that delivers all of the tools and functionality they need to easily manage their properties.”
“Since I manage a few properties on the side, I need a platform that is cost-effective, yet comprehensive to ensure I am making the most of my time and investments,” said Dave Howell, a St. Louis, MO-based rental property manager. “Many times, when you’re going the free route, you lose the completeness of the offering and end up having to use many disparate products to meet all of your needs. With TenantCloud, I have everything I need to effectively manage my properties, and they continue to evolve to deliver features I didn’t even realize I needed.”
According to the TenantCloud Quarterly, nearly one-third of all urban rental applications on TenantCloud are from renters over the age of 60, the largest increase of any other renting age group. And more than four in 10 landlords say their average property is a single-family home.
In an effort to help landlords find more leads for vacant units and get the investment cash flowing, TenantCloud is also announcing the availability of a new feature called TenantMatch, which allows renters to create a profile with details about their preferred rental, so landlords can find them if they have a good fit.
When it comes to what landlords are looking for, the report finds they rank eviction history and a high credit score at the top of their list for the most important information about a possible tenant. And ‘paying on time,’ is the number one characteristic of their ideal tenant. Most landlords say their average tenants are families (54 percent). And while 78 percent say the ages of their tenants have remained the same in the past five years, 13 percent say it has increased.
For the full report, visit https://www.tenantcloud.com/blog/rental-occupancy-according-to-landlords-using-tc
About TenantCloud
TenantCloud is the premier cloud-based property management solution that helps landlords maximize the revenue from their rental properties. Built as a free and comprehensive solution, TenantCloud provides landlords everything they need to manage their rental business in one place, including posting listings, collecting rent online, and screening applicants. TenantCloud is the hub for property management with a user-friendly interface that streamlines the complete rental process, from backend accounting to maintenance requests, to drive increased return on rentals for landlords. For more information, visit http://www.tenantcloud.com.

Newly Published Study Validates How Trina Health Artificial Pancreas Treatment® Can Reduce Hospitalization Rates/Costs and Reverse Neuropathy

Newly Published Study Validates How Trina Health Artificial Pancreas Treatment® Can Reduce Hospitalization Rates/Costs and Reverse Neuropathy
 

SAN CLEMENTE, Calif. & CHESTERFIELD, Mo.-(STL.NEWS)–Animo Health, Inc. dba Trina Health Midwest announced today that its Trina Health Artificial Pancreas Treatment (APT) “represents a new advance to the treatment of diabetes, due to its ability to closely replicate normal pancreatic function,” as reported in a just-published study in The Journal of Diabetes, Metabolic Disorders & Control entitled ‘Microburst Insulin Infusion: Results of Observational Studies—Carbohydrate Metabolism, Painful Diabetic neuropathy, and Hospital/Emergency Department Utilization” (Volume 4 Issue 4 2017).

The study is based on data from three observational retrospective studies that underscore the effectiveness of microburst insulin infusion.

“The Microburst Insulin Infusion Study provides a scientific validation to what we see every day in our clinics,” said Mark Pound, president and CEO of Animo Health, Inc. dba Trina Health Midwest. “After several treatments we’ve seen the Artificial Pancreas Treatment slow, stop and even reverse complications associated with Type 1 and Type 2 diabetes. Patients suffering from neuropathy can feel their feet again and become active again. Patients who were constantly fatigued now have new energy. Patients suffering from retinopathy have improved eyesight. Patients nearing dialysis treatment have been told it’s no longer needed.”

“The Artificial Pancreas Treatment is NOT a cure,” Pound emphasized. “However, it is exponentially improving our patients’ quality of life.”

The Artificial Pancreas Treatment, which more closely mimics the natural burst insulin secretion of a healthy pancreas, showed significant improvement in three observational retrospective studies: carbohydrate metabolism, painful diabetic neuropathy (PDN), and hospital/emergency department utilization.

Carbohydrate metabolism study

These results suggest that the Artificial Pancreas Treatment has a dramatic effect on carbohydrate metabolism; this is of particular importance as the inability to properly metabolize carbohydrates represents a core dysfunction in diabetes.

Painful Diabetic Neuropathy (PDN) study

Among 412 patients studied (80 percent Type 2, 20 percent Type 1) over a three month period, the Artificial Pancreas Treatment completely eliminated or significantly reduced pain in 93 percent of PDN patients.

Hospital and emergency room utilization study

The Artificial Pancreas Treatment dramatically lowers hospital utilization and hospital costs. A two-year retrospective study of 1,524 Type 1 and Type 2 diabetes patients with two or more complications was conducted at 14 centers. The Artificial Pancreas Treatment® (APT) significantly reduced the number of hospital and emergency visits. According to Matched National Hospital Discharge Survey (NHDS) and U.S. Agency for Healthcare Statistics, expected hospitalization rate is 94 per 1,000 patients over a two-year period. The APTs rate is 5. What’s more, expected emergency room visits are 116 per 1,000 patients over two years. The APT rate is 7.

Conclusion

The study stated: “In summary, conventional insulin therapy has achieved only partial success in the treatment of diabetes and prevention of chronic complications…. Microburst insulin therapy represents a new advance in the treatment of diabetes, due to its ability to closely replicate normal pancreatic function. Taken together, the rather dramatic reductions in neuropathic complications and hospital/emergency department visits, as well as the significant improvements in carbohydrate metabolism in these observational studies, may be due to the more precise mimicking of naturally pulsed insulin.”

A PDF Abstract of “Microburst Insulin Infusion: Results of Observational Studies—Carbohydrate Metabolism, Painful Diabetic Neuropathy, and Hospital/Emergency Department Utilization” can be downloaded at http://medcraveonline.com/JDMDC/JDMDC-04-00118.pdf.

About Trina Health LLC, in Partnership with Animo Health, Inc. dba Trina Health Midwest

With over 200,000 treatments with no adverse reactions and more than 24 domestic and international clinics, the Trina Health Artificial Pancreas Treatment is expanding throughout the United States and abroad. Animo Health, Inc., doing business as Trina Health Midwest, has obtained exclusive rights to establish clinics throughout Missouri and the Midwest using Trina Health’s Artificial Pancreas Treatment that can slow, halt, and/or reverse in most cases the chronic complications in Type 1 and Type 2 diabetes. Visit www.trinahealthmidwest.com for more information.

Contacts
Daly-Swartz PR for Animo Health/Trina Health Midwest
Jeffrey Swartz, 949.470.0075
[email protected]

Senate health care debate could be suspenseful and raucous

Mitch McConnell, John Barrasso, John Thune, John Cornyn - Senate health care debate could be suspenseful and raucous
Senate Majority Leader Mitch McConnell of Ky., joined by, from left, Sen. John Barrasso, R-Wyo., Sen. John Thune, R-S.D., and Majority Whip John Cornyn, R-Texas, speak with reporters on Capitol Hill in Washington, Tuesday, July 25, 2017, after Vice President Mike Pence broke a 50-50 tie to start debating Republican legislation to tear down much of the Obama health care law. (AP Photo/J. Scott Applewhite)
 

Senate health care debate could be suspenseful and raucous as the Senate’s days-long debate on health care features a dynamic that’s relatively rare

WASHINGTON/July 26, 2017 (AP)(STL.News) — The Senate’s days-long debate on health care features a dynamic that’s relatively rare on Capitol Hill.  Genuine suspense.

Debate kicked off Tuesday without an obvious endgame. Several Republicans voted to start debate but said the bill will have to be changed for them to vote to actually pass the legislation later this week. The amendment process promises to be extensive and freewheeling. And victory for Republicans and President Donald Trump is not guaranteed.

The Senate has started off by taking up the House-passed bill — which doesn’t have enough support to pass the Senate — and it’ll take near-unanimity among Republicans for them to alter the measure. Right now, they’re deeply divided.

“We obviously don’t have consensus on where we ought to go,” said Sen. Ron Johnson, R-Wis. “No matter what we pass it’s not going to fix the whole problem.”

Here’s a primer on how to watch this week’s Senate debate on repealing and replacing the Obama health law.

FAST-TRACK PROCESS

First, the legislation is being debated under fast-track budget rules that allow it to pass on a simple majority instead of having to clear the 60-vote filibuster threshold required of other legislation. Debate is limited to 20 hours. Amendments, generally speaking, are unlimited — and can be offered after debate time has expired in a Washington ritual known as “vote-a-rama.” That’s when amendment after amendment is voted on in what could be an all-night session on Thursday.

The first amendments get up to two hours of debate. During the voting marathon, debate is typically just two minutes.

AMENDMENTS GALORE

Unlike other bills, which typically are debated in ways that limit senators’ rights to offer changes known as amendments, the current bill is wide open.

“I suspect there will be literally hundreds of amendments,” said Sen. John Cornyn of Texas, the No. 2 Republican in the Senate.

The first amendment was offered by GOP leader Mitch McConnell of Kentucky. It is virtually identical to the version that passed the Senate in late 2015 that would repeal much of Obamacare and leave replacing it for later. It’s sure to lose, even though it passed less than two years ago — when skeptics of repealing the law without a clear plan for replacing it were assured of former President Barack Obama‘s veto.

Another McConnell amendment, likely to be swatted down by a parliamentary challenge by Democrats, includes the Senate’s most recent “repeal and replace” bill — scuttled last week for lack of support — along with separate provisions from Sens. Ted Cruz, R-Texas, and Rob Portman, R-Ohio.

Democrats are poised to offer dozens of amendments of their own. For instance, they could try to eliminate tax cuts rewarding investors and upper bracket earners, just for starters.
One problem: Senators don’t necessarily know how to draft amendments because they’re unsure which bill they’ll ultimately be amending.

PARLIAMENTARY PUZZLE

The special fast-track process, called reconciliation in Washington-speak, comes with tricky rules. Amendments that are carefully crafted and fit within the rules can pass on a simple majority vote. But many amendments run afoul of the Senate’s byzantine rules, which mean they can require 60 votes and effectively be blocked by Democrats.

Among them is the so-called Byrd rule, named after former Sen. Robert Byrd, D-W.Va. It’s complicated, but the Byrd rule disqualifies some of the GOP’s ideas, such as a provision in the pending bill aimed at lowering premiums paid by younger, healthier consumers by allowing insurance companies to increase premiums paid by seniors.

The Byrd rule generally blocks provisions that don’t affect the federal budget — and blocks provisions whose changes to spending or taxes are “merely incidental” to a larger policy purpose. If such provisions are inserted despite the Byrd rule, any individual senators can knock them out with a point of order.

MCCONNELL’S LAST OPTION

At the very end of the debate, after dozens of votes on amendments and parliamentary challenges, majority Republicans can offer one, final substitute amendment. McConnell would probably be the author and it could represent one final grasp at consensus among fractured Republicans.

McConnell’s last gambit could offer Republican senators a difficult choice since rejecting it would probably doom the whole effort. But consensus among Republicans has eluded McConnell for weeks, so there are plenty of reasons to be skeptical he can succeed now.

BACK TO THE HOUSE — OR INTO CONFERENCE?

If the Senate should manage to maneuver its way through this week’s legislative labyrinth, the resulting bill could go back to the House for a vote that would send it directly to Trump for his signature.

The other alternative would be to send the measure into official House-Senate negotiations known as a conference committee. Conference talks, insiders fear, could be a nightmare and invite balkanized Republicans to feud even more. In particular, tea party House Republicans and the Senate’s more pragmatic GOP wing could be in for a fight.

___

By ANDREW TAYLOR and STEPHEN OHLEMACHER, Associated Press – STL.News publisher St. Louis Media, LLC

___

STL.News Sitemap

St. Louis: Current Weather Conditions & Forecast & Air Quality Index-July 26th am

St. Louis: Current Weather Conditions & Forecast & Air Quality Index-July 26th am
St. Louis: Current Weather Conditions & Forecast & Air Quality Index-July 26th am (Picture licensed to St. Louis Media, LLC d.b.a. STL.News by BigStockPhoto.com)
 

Current weather conditions at St. Louis Lambert International Airport and Air Quality Index for St. Louis

ST. LOUIS, MO/July 25, 2017 (STL.News) Weather conditions @ Lambert Airport – St. Louis International Airport – Latitude: 38.75°N – Longitude: 90.37°W – Elevation 604 feet.

Sky: A Few Clouds
Temperature: 79°F – 26°C
Humidity: 74%
Wind Speed: SE 9 mph
Barometer: 30.05 in (1016.1 mb)
Dewpoint: 70°F – 21°C
Visibility: 10.00 miles
Heat Index: 82°F – 28°C
Last Update: 26, July 2017 4:51 a.m. CDT

Extended Forecast for St. Louis, MO

Today: Mostly sunny and hot – high near 99. Heat index values as high as 107. Southeast wind 5 to 8 mph becoming west in the afternoon.
Tonight: Showers and thunderstorms likely, mainly after 3 am. Mostly cloudy – low around 79. South wind 5 to 7 mph. Chance of precipitation is 70%.
Thursday: Showers and thunderstorms likely. Cloudy – high near 88. Southwest wind 5 to 7 mph becoming northwest in the afternoon. Chance of precipitation is 70%.
Thursday Night: A 40 percent chance of showers and thunderstorms before 1 am. Mostly cloudy – low around 70. North wind around 6 mph.
Friday: Mostly sunny – high near 85. North wind 5 to 8 mph.
Friday Night: Mostly clear – low around 65.
Saturday: Sunny – high near 85.
Saturday Night: Mostly clear – low around 63.
Sunday: Sunny – high near 85.
Sunday Night: Mostly clear – low around 65.
Monday: Sunny – high near 87.
Monday Night: Mostly clear – low around 67.
Tuesday: Sunny – high near 89.

AQI (Air Quality Index)

Current Air Quality: 07/26/17 1:00 AM CDT

  • Moderate – 57 AQI – Particle Pollution (2.5 microns)
  • Moderate – 51 AQI – Ozone
  • Good – 19 AQI – Particle Pollution (10 microns)

Agency: St. Louis Metropolitan Area (American Lung Association)
Last Update: Wed, 26 Jul 2017 01:45:10 CDT

AQI Indicator

Good – Air quality in considered “satisfactory” and air pollution poses little to no threat.

Moderate – Air quality is considered “acceptable”. However, some pollutants there may be a moderate health concern for a very small number of people who are sensitive to air pollution.

USG – while the general public will not likely be affected by this AQI range, people with lung disease, older adults and children are a great risk from exposure to ozone, whereas, persons with heart and lung disease, old adults and children are at greater risk from the presence of particles in the air.

Unhealthy – Everyone may begin to experience health effects members of sensitive groups may experience more serious health effects.

Very Unhealthy – Health Alert: everyone may experience more serious health effects.

___

Source: Weather from Forecast.Weather.Gov – AQI from AirNow.Gov – STL.News publisher, St. Louis Media, LLC

___

Wikipedia: Air Quality IndexNational Weather Service

___

STL.News Sitemap

World shares mostly higher as markets await Fed’s decision

Japan Financial Markets - World shares mostly higher as markets await Fed's decision
Passers-by look at an electronic stock indicator of a securities firm in Tokyo, Wednesday, July 26, 2017. Asian stock markets are mixed Wednesday, with upward momentum from a record day on Wall Street and buoyant oil prices offset by investor caution ahead of the Fed's upcoming interest rate decision. (AP Photo/Shizuo Kambayashi)
 

HONG KONG/July 26, 2017 (AP)(STL.News)(Keywords: World shares, Fed’s decision) — World stock markets were mostly higher Wednesday, lifted by another record day on Wall Street and buoyant oil prices. Investors were keeping a cautious eye on the Fed’s upcoming interest rate decision.

KEEPING SCORE: European shares rose in early trading. France’s CAC 40 added 0.7 percent to 5,196.27 and Germany’s DAX climbed 0.4 percent to 12,309.31. Britain’s FTSE 100 rose 0.6 percent to 7,477.89. U.S. shares were poised to open higher. Dow futures were up 0.1 percent to 21,581.00 and broader S&P 500 futures edged up 0.1 percent to 2,476.10.

FED IN FOCUS: The U.S. central bank’s policy-making committee is holding a two-day meeting, where most analysts expect officials to keep rates unchanged. The Fed has already raised rates three times since December and market watchers don’t expect another hike until later this year or in 2018.

ANALYST VIEW: “Today’s FOMC meeting is likely to be a non-event,” said Lukman Otunuga, an analyst at FXTM. “Investors most probably will use this opportunity to closely scrutinize the policy statement for clues on the Federal Reserve’s tightening plan,” he said, adding that markets will also be looking for hints on how the Fed plans to reduce its massive $4.5 billion in bond holdings and its view on inflation.

EARNINGS SEASON: Investors are assessing the latest round of quarterly earnings reports. Better than expected profits at U.S. companies like McDonald’s and Caterpilllar helped propel Wall Street to another record day. In Asia, Nintendo Co.’s Switch hybrid game machine helped the Japanese video-game maker swing into a $190 million profit, reversing from a loss from the previous year. South Korean auto maker Hyundai Motor’s quarterly profit fell by half because of weakness in its SUV lineup.

ASIA’S DAY: Japan’s benchmark Nikkei 225 index climbed 0.5 percent to close at 20,050.16 but South Korea’s Kospi index slipped 0.2 percent to 2,434.51. Hong Kong’s Hang Seng index added 0.3 percent to 26,941.02 and the Shanghai Composite index edged up 0.1 percent to 3,247.67. Australia’s S&P/ASX 200 rallied 0.9 percent to 5,776.60. India’s Sensex gained 0.3 percent to 32,338.57 and benchmarks in Southeast Asia were mostly higher.

ENERGY: Oil futures extended gains in Asian trading. Benchmark U.S. crude added 37 cents to $48.26 a barrel in electronic trading on the New York Mercantile Exchange. The contract rose $1.55, or 3.3 percent, to settle at $47.89 per barrel on Tuesday. Brent crude, the international standard, gained 35 cents to $50.71 a barrel in London.

CURRENCIES: The dollar weakened to 111.86 yen from 111.91 yen late Tuesday. The euro slipped to $1.1624 from $1.1649.

___

By KELVIN CHAN, AP Business Writer – STL.News publisher St. Louis Media, LLC

___

STL.News Sitemap

St. Louis: Current Weather Conditions & Forecast & Air Quality Index-July 25th pm

St. Louis: Current Weather Conditions & Forecast & Air Quality Index-July 25th pm
St. Louis: Current Weather Conditions & Forecast & Air Quality Index-July 25th pm (Picture licensed to St. Louis Media, LLC d.b.a. STL.News by BigStockPhoto.com)
 

Current weather conditions at St. Louis Lambert International Airport and Air Quality Index for St. Louis

ST. LOUIS, MO/July 25, 2017 (STL.News) Weather conditions @ Lambert Airport – St. Louis International Airport – Latitude: 38.75°N – Longitude: 90.37°W – Elevation 604 feet.

Sky: A Few Clouds
Temperature: 88°F – 31°C
Humidity: 55%
Wind Speed: E 14 mph
Barometer: 30.05 in (1016.4 mb)
Dewpoint: 70°F – 21°C
Visibility: 10.00 miles
Heat Index: N/A
Last Update: 25, July 2017 7:51 p.m. CDT

Extended Forecast for St. Louis, MO

Tonight: Mostly clear – low around 75. Southeast wind 5 to 7 mph.
Wednesday: Mostly sunny and hot – high near 98. Heat index values as high as 106. Southeast wind around 6 mph becoming southwest in the afternoon.
Wednesday Night: A 50 percent chance of showers and thunderstorms, mainly after 1 am. Mostly cloudy – low around 78. South wind 3 to 6 mph.
Thursday: A 50 percent chance of showers and thunderstorms. Mostly cloudy – high near 88. Southwest wind 5 to 7 mph becoming northwest in the afternoon.
Thursday Night: A 30 percent chance of showers and thunderstorms before 1 am. Mostly cloudy – low around 69. North wind around 6 mph.
Friday: Mostly sunny – high near 85.
Friday Night: Mostly clear – low around 64.
Saturday: Sunny – high near 84.
Saturday Night: Mostly clear – low around 64.
Sunday: Sunny – high near 85.
Sunday Night: Mostly clear – low around 66.
Monday: Mostly sunny – high near 87.
Monday Night: Partly cloudy – low around 68.
Tuesday: Mostly sunny – high near 88.

AQI (Air Quality Index)

Current Air Quality: 07/25/17 6:00 PM CDT

  • Moderate – 97 AQI – Ozone
  • Moderate – 65 AQI – Particle Pollution (2.5 microns)
  • Good – 22 AQI – Particle Pollution (10 microns)

Agency: St. Louis Metropolitan Area (American Lung Association)
Last Update: Tue, 25 Jul 2017 07:15:09 CDT

AQI Indicator

Good – Air quality in considered “satisfactory” and air pollution poses little to no threat.

Moderate – Air quality is considered “acceptable”. However, some pollutants there may be a moderate health concern for a very small number of people who are sensitive to air pollution.

USG – while the general public will not likely be affected by this AQI range, people with lung disease, older adults and children are a great risk from exposure to ozone, whereas, persons with heart and lung disease, old adults and children are at greater risk from the presence of particles in the air.

Unhealthy – Everyone may begin to experience health effects members of sensitive groups may experience more serious health effects.

Very Unhealthy – Health Alert: everyone may experience more serious health effects.

___

Source: Weather from Forecast.Weather.Gov – AQI from AirNow.Gov – STL.News publisher, St. Louis Media, LLC

___

Wikipedia: Air Quality IndexNational Weather Service

___

STL.News Sitemap

US stocks back to records as corporate profits keep rising

Financial Markets Wall Street - US stocks back to records as corporate profits keep rising
This Tuesday, Oct. 25, 2016, file photo shows the New York Stock Exchange, in lower Manhattan. Stock markets turned higher on Tuesday, July 25, 2017, as investors monitored a slew of corporate earnings reports. A meeting of the Federal Reserve and caution over potential twists and turns in U.S. politics kept most indexes trading within a narrow range. (AP Photo/Mary Altaffer, File)
 

NEW YORK/July 25, 2017 (AP)(STL.News)(Keywords: US stocks, corporate profits) — U.S. stock indexes returned to records Tuesday as corporate profits continue to come in better than analysts expected.

McDonald’s and Caterpillar were among the big companies that reported healthier-than-forecast results. Sharp moves higher in prices for oil, metals and other commodities also helped lift companies that produce energy and raw materials. That more than offset losses for health care companies and stocks that pay relatively big dividends, which were hurt by a rise in Treasury yields.

The Standard & Poor’s 500 rose 7.17 points, or 0.3 percent, to an all-time high of 2,477.08. It was the first gain for the index in four days.

The Dow Jones industrial average rose 100.26, or 0.5 percent, to 21,613.43. The Nasdaq composite added 1.37 points, or less than 0.1 percent, to 6,412.17, and the Russell 2000 index of small-cap stocks gained 12.33, or 0.9 percent, to 1,450.39. Both the Nasdaq and Russell set records.

Leading the way for the market were energy stocks, which benefited from a second strong day for the price of oil. Benchmark U.S. crude rose $1.55, or 3.3 percent, to settle at $47.89 per barrel. Brent crude, the international standard, gained $1.60, or 3.3 percent, to $50.20 a barrel.

That helped energy stocks in the S&P 500 climb 1.3 percent, tied for the biggest gain among the 11 sectors that make up the index. Devon Energy rose $1.24, or 3.9 percent, to $32.98, for example, while Marathon Oil gained 46 cents, or 3.9 percent, to $12.34.

Financial stocks were also strong after a pickup in interest rates raised expectations that banks could charge more for loans and pocket bigger profits.

The yield on the 10-year Treasury note climbed to 2.32 percent from 2.26 percent late Monday. The two-year yield climbed to 1.38 percent from 1.36 percent, and the 30-year yield rose to 2.91 percent from 2.83 percent.

The rise in yields came as the Federal Reserve began a two-day policy meeting on interest rates. The central bank has already raised rates three times since December, but few investors expect it to make another move when it announces its decision Wednesday. Most expect the next rate increase to come later this year.

It may not have shown on Tuesday, but many investors are bracing for markets to get shakier as the Federal Reserve moves further away record-low interest rates and big stimulus for the economy. Contrarians are also concerned about how much the stock market has climbed, and how smooth the ride has been, as expectations have built up this year for corporate profits will keep piling higher.

“There’s a lot of hope built into the market at current levels,” said Rob McIver, portfolio manager at the $6.3 billion Jensen Quality Growth fund. “We’re cautioning investors to be cautious and conservative.”

Technology stocks have been the year’s biggest stars so far, as investors have been hungry for anything with the potential to grow quickly in a slow-growing global economy. But tech stocks in the S&P 500 dipped 0.2 percent Tuesday after several reported results that fell short of expectations.

Seagate Technology sank $6.56, or 16.5 percent, to $33.20 after the maker of hard drives and other electronic data storage reported weaker revenue and earnings than analysts had forecast, for example.

On the opposite side was Caterpillar, which jumped $6.36, or 5.9 percent, to $114.54 after reporting better results for the latest quarter than analysts expected. It also raised its forecast for revenue and profit for the full year, citing increased demand across many of its markets.

McDonald’s rose $7.22, or 4.8 percent, to $159.07 after its revenue and earnings for the latest quarter topped Wall Street’s forecast. The burger chain has been drawing in customers with a new line of premium of burgers and $1 sodas.

In the commodities market, natural gas rose 5 cents to $2.94 per 1,000 cubic feet, heating oil gained 5 cents to $1.57 per gallon and wholesale gasoline climbed 4 cents to $1.60 per gallon.

Metals prices also climbed, which helped to lift shares of mining companies and other raw-material producers. Copper jumped 11 cents, or 4 percent, to $2.85 per pound, while silver rose 10 cents to $16.54 per ounce and gold slipped $2.20 to $1,252.10 an ounce.

The euro rose to $1.1652 from $1.1645 late Monday. The dollar rose to 111.89 Japanese yen from 111.11 yen, and the British pound inched up to $1.3037 from $1.3036.

France’s CAC 40 climbed 0.7 percent, Germany’s DAX gained 0.5 percent and the FTSE 100 in London rose 0.8 percent.

Japan’s Nikkei 225 index slipped 0.1 percent, South Korea’s Kospi index dipped 0.5 percent and the Han Seng in Hong Kong was virtually flat.

___

By STAN CHOE, AP Business Writer – STL.News publisher St. Louis Media, LLC

___

STL.News Sitemap

OWC Pharmaceutical Research Corp Appoints Dr. Stanley Hirsch as its Active Chairman

OWC Pharmaceutical Research Corp Appoints Dr. Stanley Hirsch as its Active Chairman
Medicinal cannabis with extracted oil in a bottle
 

OWC Pharmaceutical Research Corp Appoints Dr. Stanley Hirsch as its Active Chairman

PETACH TIKVA, Israel, July 25, 2017 (STL.NEWS) — OWC Pharmaceutical Research Corp. (OTCQB: OWCP), (“OWC” or the “Company”), a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, today announced the appointment of Dr. Stanley Hirsch as its active chairman of the board of directors.

Dr. Stanley Hirsch, age 59, has had extensive scientific, executive and board level experience for more than the past 25 years in private and publicly listed companies in bio-pharmaceutical and agricultural biotech industries, among others, including direct experience in raising capital and leading M&A activity together with multi-cultural management skills, having managed companies in Israel, Brazil, UK, China and the United States.

Mr. Mordechai Bignitz Chief Executive Officer, commented on the appointment, “I am proud and honored to have Dr. Hirsch agreeing to join OWCP and assume the role of active chairman. I have known Dr. Hirsch for many years and cooperated with him in the past. Dr. Hirsch brings with him a unique set of skills, both scientific and business, that are in the exact scope of our operations. I am sure that his contribution to our growth will be of major significance.

Dr. Stanley Hirsch commented on his new role “I feel privileged to have received the invitation to serve as OWCP’s active chairman. I have known Mr. Bignitz for more than 20 years and we cooperated extremely successfully in the past. I received an in depth scientific overview from OWCP’s CSO, Dr. Yehuda Baruch and I am sure OWCP’s intellectual assets and scientific achievements position it most advantageously to become a world leader in the field of Cannabis based scientific products.

About OWC Pharmaceutical Research Corp.

OWC Pharmaceutical Research Corp., through its wholly-owned Israeli subsidiary, One World Cannabis Ltd., (collectively ‘OWC’ or the ‘Company’) conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines.

OWCP is also developing unique delivery systems for the effective delivery and dosage of medical cannabis. All OWCP research is conducted at leading Israeli hospitals and scientific institutions and led by internationally renowned investigators. The Company’s Research Division is focused on pursuing clinical trials evaluating the effectiveness of cannabinoids and cannabis-based products for the treatment of various medical conditions, while its Consulting Division is dedicated to helping governments and companies navigate complex international cannabis regulatory frameworks.

For more information visit: http://www.owcpharma.com/.

Notice Regarding Forward-Looking Statements

This news release contains “forward-looking statements” as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release, which are not purely historical, are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, filing patent applications, product development, and business strategy. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should review all of the information set forth herein and should also review the risk factor disclosure contained in the OWC Pharmaceutical Research Corp. (OTCQB: OWCP) annual report on Form 10-K and other disclosure included in OWCP’s quarterly and other reports filed from time-to-time with the Securities and Exchange Commission.

Contact Information::
Mordechai Bignitz , Chief Executive Officer – OWC Pharmaceutical Research Corp.,
Email: [email protected]
Tel: +972-(0)3-7582659

___

SOURCE: OWC Pharmaceutical Research Corp. – STL.News publisher St. Louis Media, LLC

Potential Blockbuster Treatment for Alzheimer’s Disease Stands Out Among Medical Cannabis Companies

Potential Blockbuster Treatment for Alzheimer's Disease Stands Out Among Medical Cannabis Companies
Potential Blockbuster Treatment for Alzheimer's Disease Stands Out Among Medical Cannabis Companies
 
NEW YORK, July 25, 2017(STL.NEWS)–Changes in public opinion regarding cannabis have greatly fueled the fire blazing under the red-hot state-legalized marijuana market. A recent Gallup poll shows that 60 percent of Americans now support the legalization of marijuana[1], while another report shows that marijuana sales jumped an incredible 30 percent in North America in 2016 to reach $6.7 billion[2]. While many investors are looking to find profitable plays in this burgeoning market, continuing federal restrictions make medical marijuana one of the safest investment routes. Standout companies that present prime opportunities in this space include India Globalization Capital, Inc. (NYSE: IGC) (IGC Profile), Cara Therapeutics, Inc. (NASDAQ: CARA), Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), Cannabis Science Inc. (OTC: CBIS) and Vitality Biopharma, Inc. (OTC: VBIO).
India Globalization Capital, Inc. (NYSE MKT: IGC) is currently readying four cannabinoid products for medical trials, including a potential blockbuster treatment for Alzheimer’s disease. Although there are about a dozen publicly-traded cannabis pharmaceutical stocks currently on the market, IGC is the only one to have patent filings for a potential cannabis-based Alzheimer’s breakthrough. Compared to its peers, IGC’s market cap of just over $10.8 million begs the question of whether the value of this innovator is under pegged. A look at the broader market and the company’s developments provide further insight.

Alzheimer’s, the most common cause of dementia among older adults is a chronic neurodegenerative disease that progressively destroys memory and cognitive skills. Alzheimer’s is the sixth-leading cause of death in the United States and will cost the nation an estimated $259 billion in 2017, according to information from the Alzheimer’s Association[3]. The breakthrough potential of IGC’s IGC-AD1 (Hyalolex), which targets the reduction of beta-amyloid buildup in Alzheimer’s patients and lessen some of Alzheimer’s worst symptoms, could be astronomical.

The accumulation of amyloid plaque on neurons in the brain is believed to be the major cause of Alzheimer’s disease. IGC recently acquired exclusive rights (http://nnw.fm/3QaWV) to its novel tetrahydrocannabinol (THC)-based treatment for Alzheimer’s from the University of South Florida, where research using an animal model showed the reversal of amyloid plaque buildup. The lead investigator at the university used cannabis extract on transgenic mice and discovered that the cannabis extract actually reversed beta-amyloid accumulation. What this indicates is a potential means of restoring memory function in Alzheimer’s patients, a game-changing development indeed. IGC expects to begin human trials this year.

Under the definitive license agreement with the University of South Florida, IGC is the exclusive licensee of the patent filing ‘THC as a Potential Therapeutic Agent for Alzheimer’s Disease,’ which claims the discovery of a new pathway in which low doses of THC bind to beta-amyloid plaques and prevent them from aggregating on neurons, the very process that is linked to causing cognitive decline in Alzheimer’s patients. This new pathway offers exciting potential in the treatment of Alzheimer’s, and, if the patent is granted and proven, IGC will own the rights to it. Acquisition of the patent additionally helps IGC protect its proprietary formulation of IGC-AD1. The lead investigator at the University of South Florida now helping IGC was featured on CNN by Dr. Sanjay Gupta on the ‘Weed 3, The Marijuana Revolution,’ available for viewing at http://www.igcinc.us.

In addition to IGC-AD1, the company’s other cannabis-based products currently moving toward trials include Natrinol for the treatment of cachexia in AIDS and cancer patients; Serosapse, which addresses various Parkinson’s disease endpoints; and Caesafin, which employs combination therapy to alleviate seizures in dogs and cats. Other companies we have seen with this kind of cannabis based runaway potential, have market capitalizations between $25 million to $500 million as compared to IGC’s $10 million market cap.

When it comes to market value, the heavyweight of this group is clinical-stage biopharmaceutical company Cara Therapeutics, Inc. (NASDAQ: CARA), which has a market cap of $506.1 million. Focused on the development and commercialization of new chemical entities that are designed to alleviate pain and pruritus through the selective targeting of peripheral kappa opioid receptors, the company is developing a novel, proprietary class of product candidates that target the peripheral nervous system and have shown initial efficacy in patients with moderate to severe pain without creating many of the unwanted side effects that are typically associated with current pain therapeutics. The company’s CR701 candidate is a cannabinoid receptor agonist designed to reduce pain.

Perhaps most similar to IGC in terms of product candidates and an early-stage pipeline is Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), a clinical-stage pharmaceutical company engaged in developing innovative transdermal synthetic cannabinoid treatment for patients who have high unmet medical needs. As of July 18, Zynerba’s market cap stood at $251.7 million – a far cry above IGC’s market valuation. Zynerba’s development pipeline includes two lead product candidates that are being evaluated in five therapeutic indications. ZYN002 is the first and only synthetic CBD and has been formulated as a patent-protected permeation enhanced gel for transdermal delivery through the skin and into the body’s circulatory system. It is currently in phase 2 clinical developments in patients with refractory epilepsy, osteoarthritis of the knee and Fragile X syndrome. The company’s ZYN001 is a pro-drug of THC that facilitates transdermal delivery through the skin and into the circulatory system by means of a patch. A phase 1 clinical program for ZYN001 commenced in the first half of 2017.

Another small-cap player – with a market cap of $120.2 million – is Cannabis Science, Inc. (OTC: CBIS), a company focused on developing cannabinoid-based medicines to provide innovative treatment options for unmet medical needs, with an immediate focus on treating cancer. The company is working with leading experts to develop, produce and commercialize novel therapeutic approaches to treat a variety of critical ailments, from cancer and infections to age-related illnesses and neurobehavioral disorders. The company’s current development programs include CS-TATI-1, which will be targeted at both newly diagnosed and treatment-experienced patients with drug-resistant HIV strains and those that are intolerant to current therapies; CS-S/BCC-1 for skin cancer; and CS-NEURO-1 for various neurobehavioral disorders, including ADHD and anxiety.

Vitality Biopharma, Inc. (OTCQB: VBIO), another medical marijuana company, is focused on applying the power of cannabinoids to treat serious neurological and inflammatory disorders and currently has a market cap of $40.2 million. VBIO is developing proprietary cannabinoid prodrug pharmaceuticals that are FDA- and DEA-compliant. The company believes oral cannabinoid pharmaceuticals can help the full therapeutic potential of cannabinoid medicines to be realized. Oral prodrugs allow for a regulatory strategy that has a lower risk and is similar to specialty pharmaceutical development. VBIO is leveraging existing clinical studies that demonstrate the efficacy of cannabinoids in treating inflammatory bowel disease, Nijmegen breakage syndrome (NBS), multiple sclerosis, neuropathic pain and other disease indications. The company has developed a new class of cannabinoid prodrugs called cannabosides that can be targeted and limited to the body’s gastrointestinal tract to prevent drug psychoactivity and unanticipated side effects.

The spectrum of market value for these cannabis-based pharmaceutical players’ swings across the board, and India Globalization Capital has several aspects that may warrant a higher valuation. While each of the above-named companies present an opportunity to invest in the rapidly advancing medical cannabis space, investors looking for an entry point through an undervalued company may want to take a closer look at India Globalization Capital, Inc. (NYSE: IGC).

___

Editorial Sources:

(1) Gallup http://nnw.fm/CPS7h

(2) Arcview http://nnw.fm/zE44Q

(3) Alzheimer’s Association http://nnw.fm/LpC8P

For more information on India Globalization Capital, please visit: India Globalization Capital (IGC) or http://www.igcinc.us

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

 

TricorBraun Packaging Options Direct Launches Online Credit Application

TricorBraun Packaging Options Direct Launches Online Credit Application
 

ST. LOUIS, July 25, 2017 (STL.NEWS) — Packaging Options Direct, a division of TricorBraun, has launched a new, online credit application tool, according to Nicholas Jager, Operations Manager at Packaging Options Direct.

“Our new credit tool has been developed to make the line-of-credit process easier and more convenient for customers,” said Jager. He said new customers that have registered can now apply for credit online when their cart subtotal is over $1000 at: https://packagingoptionsdirect.com/

According to Jager, new or returning customers checking out with a subtotal of at least $1,000 will be offered $2,500 worth of credit. Customers who have applied for credit and been approved, can then use their line of credit for any size order.

“In addition, customers that seek a larger credit line, or who currently do business with TricorBraun, can leverage this payment option as well,” said Jager. “They can call 1-877-706-1035, to get started.”

Line-of-credit terms and requirements for this new online application include:

Credit extended to businesses only, not individuals
Complete address information including bill to address, accounts payable contact, phone and email address
Valid Tax ID number
Good Standing with Secretary of State
Acceptance of Terms and Conditions
Electronic Signature
Optional:
D & B Number
Resale Certificate documents (if applicable for tax exempt status)
For more information on the new credit application at Packaging Options Direct, visit: http://packagingoptionsdirect.com/introducing-our-online-credit-application-and-terms.

About Packaging Options Direct
Packaging Options Direct (http://packagingoptionsdirect.com) is a division of TricorBraun. Developed in 2011, as an online marketplace for emerging businesses, Packaging Options Direct has become the leading online wholesale marketplace, supplying the bottles, jars, cans, containers, tins, scoops, pumps and closures needed to create ideas and grow dreams.

About TricorBraun
TricorBraun (www.tricorbraun.com) is a packaging solutions company, focused on providing innovative, custom solutions for its many customers. An industry leader in glass and plastic containers, closures, dispensers and tubes, TricorBraun operates from more than 40 locations throughout North America and internationally from London, England: Guangzhou, China; Hong Kong, and Mumbai, India. Our award-winning Design & Engineering Center provides forward-thinking service driven by consumer insight, market understanding and creative solutions. TricorBraun’s advisory services range from preliminary planning and manufacturing oversight to warehousing and logistics programs.

SOURCE TricorBraun